Hematology Research
The research activities in hematology include both clinical and laboratory research. Details of research interests of each faculty are noted in their individual pages.
Current areas of laboratory research programs include immunobiology of plasma cell diseases, and cellular and molecular biology of blood cell production and hematopoiesis. The research activities are funded by the National Institutes of Health.
Areas of clinical research interest include myeloma and related plasma cell disorders, coagulopathies and non-malignant hematology, sickle cell disease, and palliative care. Other faculty affiliated with the section also carry out basic and clinical research related to hematology. Research programs in hematologic malignancies are in close collaboration with colleagues in the Hematology Program at Yale Cancer Center.
In addition to the individual research programs of primary faculty members of the Section of Medical Oncology and Hematology, collaborative research projects are ongoing with faculty members of several other departments, such as Laboratory Medicine, Pathology, Immunobiology, and Genetics, who have common research interests.
Publications
- Newest First
- Most Cited
- Most Discussed
Showing 1 - 100 results of 603 publications
2025
- Beyond the Marrow–Moving Toward a Systemic Perspective of Radiation-Induced CytopeniasBrowning S, Lourdes M, Neparidze N, Robinson T. Beyond the Marrow–Moving Toward a Systemic Perspective of Radiation-Induced Cytopenias. International Journal Of Radiation Oncology • Biology • Physics 2025, 121: 1039-1041. PMID: 39988417, DOI: 10.1016/j.ijrobp.2024.11.100.
- FieldsAlpert AB. Fields. JAMA. 2025;333(4):352. doi:10.1001/jama.2024.18180
2024
- Recent Insights of Molecular Approaches to Study Brain Tumor Associated Seizure and EpilepsyDr. Rajesh Kumar Kar,"Recent Insights of Molecular Approaches to Study Brain Tumor Associated Seizure and Epilepsy", Recent Trends in Diabetes and Cancer Research and its Management,IIP Series, Volume 1, September, 2024, Page no.21-47, e-ISBN: 978-1-68576-521-7, DOI/Link: https://www.doi.org/10.58532/nbennurrdch2
- The role of alternative splicing and splicing factors in diabetes: Current status and future perspectivesSingha, D., Mondal, M., Ghosh, D., Choudhury, D., Chakravarti, B., Kar, R. K., & Malakar, P. (2024). The role of alternative splicing and splicing factors in diabetes: Current status and future perspectives. WIREs RNA, 15(1), e1831. https://doi.org/10.1002/wrna.1831
- The nexus of long noncoding RNAs, splicing factors, alternative splicing and their modulations.Malakar P, Shukla S, Mondal M, Kar RK, Siddiqui JA. The nexus of long noncoding RNAs, splicing factors, alternative splicing and their modulations. RNA Biol 2024, 21: 1-20. PMID: 38017665, DOI: 10.1080/15476286.2023.2286099.
2023
- Comparative Studies of Mesial Temporal Lobe Epilepsy with Epilepsy from Brain TumorsKar RK. 2023. Comparative Studies of Mesial Temporal Lobe Epilepsy with Epilepsy from Brain Tumors, p 18. In Dubey SRKSKNK (ed), Socio-Scientific Interaction in Diabetes and Cancer and Its Management, 1st ed doi:10.9734/bpi/mono/978-81-968135- 7-4/CH3. B P International, India
- A possible novel therapeutic targets of Selinexor in acute lymphoblastic leukemia: a comprehensive reviewDOI: http://dx.doi.org/10.18053/jctres.09.202306.23-00088
- Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple MyelomaBrowning S, Li A, Parker T, Bar N, Anderson T, Stevens E, Liu Y, Matthews M, VanOudenhove J, Cardone R, Sun Q, Hale R, Halene S, Kibbey R, Neparidze N. Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma. Blood 2023, 142: 4774. DOI: 10.1182/blood-2023-186401.
- Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) RegistryPine A, Butt A, Garcia-Milian R, Gu S, Restrepo V, Chock Y, Hwa J, Tormey C, Rinder H, Goshua G, Belmont H, Bertolaccini M, Branch D, Erhan D, Kello N, Knight J, Petri M, Willis R, Lee A, Sharda A. Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry. Blood 2023, 142: 2575. DOI: 10.1182/blood-2023-185232.
- Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023)Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.
- ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability controlGao Y, Zimmer J, Vasic R, Liu C, Gbyli R, Zheng S, Patel A, Liu W, Qi Z, Li Y, Nelakanti R, Song Y, Biancon G, Xiao A, Slavoff S, Kibbey R, Flavell R, Simon M, Tebaldi T, Li H, Halene S. ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability control. Cell Reports 2023, 42: 113163. PMID: 37742191, PMCID: PMC10636609, DOI: 10.1016/j.celrep.2023.113163.
- Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemiaPodoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.
- P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19‐CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCELRasheed Y, Mirza A, Pine A, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19‐CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL. HemaSphere 2023, 7: e19857ae. PMCID: PMC10430478, DOI: 10.1097/01.hs9.0000972428.19857.ae.
- P1637: PROTEOMIC PROFILING OF DIFFERENT ANTIPHOSPHOLIPID ANTIBODY‐POSITIVE PHENOTYPES: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) REGISTRYButt A, Garcia‐Milian R, Goshua G, Gu S, Hwa J, Chun H, Belmont H, Kello N, Branch D, Petri M, Knight J, Willis R, Bertolaccini M, Erkan D, Lee A, Sharda A, Pine A. P1637: PROTEOMIC PROFILING OF DIFFERENT ANTIPHOSPHOLIPID ANTIBODY‐POSITIVE PHENOTYPES: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) REGISTRY. HemaSphere 2023, 7: e160607f. PMCID: PMC10429839, DOI: 10.1097/01.hs9.0000973420.16060.7f.
- P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCELMirza A, Pine A, Hamouche R, Rasheed Y, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL. HemaSphere 2023, 7: e1847498. PMCID: PMC10430598, DOI: 10.1097/01.hs9.0000972412.18474.98.
- Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MMWong S, Hamidi H, Costa L, Bekri S, Neparidze N, Vij R, Nielsen T, Raval A, Sareen R, Wassner-Fritsch E, Cho H. Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM. Frontiers In Immunology 2023, 14: 1085893. PMID: 37559718, PMCID: PMC10408441, DOI: 10.3389/fimmu.2023.1085893.
- Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United StatesPotnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.
- Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherenceShallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.
- An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDSStahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Advances 2023, 7: 2709-2714. PMID: 36260702, PMCID: PMC10333740, DOI: 10.1182/bloodadvances.2022008747.
- FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical OutcomesAvery J, Kim R, Cheng W, Foss F, Girardi M. FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes. JID Innovations 2023, 3: 100212. PMID: 37674691, PMCID: PMC10477749, DOI: 10.1016/j.xjidi.2023.100212.
- Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine ProtectionKim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.
- Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphomaPotnis K, Huntington S. Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma. Blood Advances 2023, 7: 2573-2574. PMID: 36745098, PMCID: PMC10242627, DOI: 10.1182/bloodadvances.2023009864.
- Diversity, equity, and inclusion (DEI) and health equity (HE) education in hematology/oncology (HO) fellowship: A longitudinal curriculum.Ansari N, Fanucci K, Burtness B, Goldberg S, Hurwitz M, Podoltsev N, Lee A, Kunz P. Diversity, equity, and inclusion (DEI) and health equity (HE) education in hematology/oncology (HO) fellowship: A longitudinal curriculum. Journal Of Clinical Oncology 2023, 41: 11002-11002. DOI: 10.1200/jco.2023.41.16_suppl.11002.
- A multifaceted approach to wellness in a hematology/oncology fellowship program.Srikumar T, Ansari N, Fanucci K, Goldberg S, Hurwitz M, Podoltsev N, Lee A, Sanft T. A multifaceted approach to wellness in a hematology/oncology fellowship program. Journal Of Clinical Oncology 2023, 41: 11006-11006. DOI: 10.1200/jco.2023.41.16_suppl.11006.
- Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States. Annals Of Internal Medicine 2023, 176: 779-787. PMID: 37247420, PMCID: PMC10370480, DOI: 10.7326/m22-3272.
- A New Model for Diagnosing Sepsis-induced Disseminated Intravascular Coagulation (DIC) in Patients With Coagulopathy of Liver Disease--Moving Away From Factor VIII (FVIII) and International Society on Thrombosis and Hemostasis (ISTH) DIC Scores "C. Allen, M. Heskel, A. Butt, A. Pine, A. Lee, and S. Gautam. A New Model for Diagnosing Sepsis-induced Disseminated Intravascular Coagulation (DIC) in Patients With Coagulopathy of Liver Disease--Moving Away From Factor VIII (FVIII) and International Society on Thrombosis and Hemostasis (ISTH) DIC Scores (abstract). Am J Respir Crit Care Med 2023;207:A6391.
- Supportive Care for Patients With Myelodysplastic SyndromesStempel J, Podoltsev N, Dosani T. Supportive Care for Patients With Myelodysplastic Syndromes. The Cancer Journal 2023, 29: 168-178. PMID: 37195773, DOI: 10.1097/ppo.0000000000000661.
- Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic MalignanciesPatel M, Donnellan W, Byrne M, Asch A, Zeidan A, Baer M, Fathi A, Kuykendall A, Zheng F, Walker C, Cheng L, Marando C, Savona M. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma & Leukemia 2023 DOI: 10.1016/j.clml.2023.05.002.
- Myelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and TreatmentsRose M, Zeidan A. Myelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments. The Cancer Journal 2023, 29: 109-110. PMID: 37195765, DOI: 10.1097/ppo.0000000000000663.
- Abstract 6100: The Fanconi Anemia pathway protein complex FANCI/FANCD2 couples the DNA damage response to R-loop regulation through SRSF1-mediated mRNA exportOlazabal-Herrero A, Liang F, Dutta A, Huang Y, Liang Z, Gupta A, Teng Y, Lan L, Chen X, Pei H, Pillai M, Sung P, Kupfer G. Abstract 6100: The Fanconi Anemia pathway protein complex FANCI/FANCD2 couples the DNA damage response to R-loop regulation through SRSF1-mediated mRNA export. Cancer Research 2023, 83: 6100-6100. DOI: 10.1158/1538-7445.am2023-6100.
- Abstract 798: SeroNet Pooling Project of immunocompromised populationsKazemain E, Figueiredo J, Skarbinski J, McBride R, Simon V, Karger A, Lee F, Hirsch F, Cox A, Klein S, Fan R, Halene S, Zidar D, Crawford J, Thyagarajan B, Gleason C, Mathson A, Srivastava K, Moshele P, Amoss T, Runnstrom M, Linderman S, Rodilla A, Mack P, Shyr Y, Yin A, Shea P, VanOudenhove J, Siddiqui H, Wilson B, Elkin E, Hsiao C, Ziemba Y, Schleicher C, Fox S, Kushi L, Reckamp K, Merchant A, Merin N. Abstract 798: SeroNet Pooling Project of immunocompromised populations. Cancer Research 2023, 83: 798-798. DOI: 10.1158/1538-7445.am2023-798.
- Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signalingFeng X, Sun R, Lee M, Chen X, Guo S, Geng H, Müschen M, Choi J, Pereira J. Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling. ELife 2023, 12: e83533. PMID: 36912771, PMCID: PMC10042536, DOI: 10.7554/elife.83533.
- Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphomaPotnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.
- Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyureaWang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.
- High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seqLiu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, Deng Y, Nam J, Gao F, Bordignon P, Cassano M, Tomayko M, Xu M, Halene S, Craft J, Hafler D, Fan R. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nature Biotechnology 2023, 41: 1405-1409. PMID: 36823353, PMCID: PMC10567548, DOI: 10.1038/s41587-023-01676-0.
- “Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutationChen P, Gorshein E, Tormey C, Siddon A, Perincheri S. “Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation. American Journal Of Hematology 2023, 98: 984-988. PMID: 36688500, DOI: 10.1002/ajh.26856.
- Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populationsRen J, Qu R, Rahman N, Lewis J, King A, Liao X, Mirza F, Carlson K, Huang Y, Gigante S, Evans B, Rajendran B, Xu S, Wang G, Foss F, Damsky W, Kluger Y, Krishnaswamy S, Girardi M. Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations. Blood Advances 2023, 7: 445-457. PMID: 35947128, PMCID: PMC9979716, DOI: 10.1182/bloodadvances.2022008168.
- Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysisDi M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.
- 3124 – ANALYSIS OF TRANSCRIPTOMIC AND EPITRANSCRIPTOMIC EFFECTS OF THE ACUTE MEGAKARYOBLASTIC LEUKEMIA FUSION PROTEIN RBM15-MKL1Mayday M, Biancon G, Moratti I, Pintado-Urbanc A, Simon M, Tebaldi T, Halene S, Krause D. 3124 – ANALYSIS OF TRANSCRIPTOMIC AND EPITRANSCRIPTOMIC EFFECTS OF THE ACUTE MEGAKARYOBLASTIC LEUKEMIA FUSION PROTEIN RBM15-MKL1. Experimental Hematology 2023, 124: s111. DOI: 10.1016/j.exphem.2023.06.231.
2022
- NIH SenNet Consortium to map senescent cells throughout the human lifespan to understand physiological healthLee P, Benz C, Blood P, Börner K, Campisi J, Chen F, Daldrup-Link H, De Jager P, Ding L, Duncan F, Eickelberg O, Fan R, Finkel T, Furman D, Garovic V, Gehlenborg N, Glass C, Heckenbach I, Joseph Z, Katiyar P, Kim S, Königshoff M, Kuchel G, Lee H, Lee J, Ma J, Ma Q, Melov S, Metis K, Mora A, Musi N, Neretti N, Passos J, Rahman I, Rivera-Mulia J, Robson P, Rojas M, Roy A, Scheibye-Knudsen M, Schilling B, Shi P, Silverstein J, Suryadevara V, Xie J, Wang J, Wong A, Niedernhofer L, Wang S, Anvari H, Balough J, Benz C, Bons J, Brenerman B, Evans W, Gerencser A, Gregory H, Hansen M, Justice J, Kapahi P, Murad N, O’Broin A, Pavone M, Powell M, Scott G, Shanes E, Shankaran M, Verdin E, Winer D, Wu F, Adams A, Blood P, Bueckle A, Cao-Berg I, Chen H, Davis M, Filus S, Hao Y, Hartman A, Hasanaj E, Helfer J, Herr B, Joseph Z, Molla G, Mou G, Puerto J, Quardokus E, Ropelewski A, Ruffalo M, Satija R, Schwenk M, Scibek R, Shirey W, Sibilla M, Welling J, Yuan Z, Bonneau R, Christiano A, Izar B, Menon V, Owens D, Phatnani H, Smith C, Suh Y, Teich A, Bekker V, Chan C, Coutavas E, Hartwig M, Ji Z, Nixon A, Dou Z, Rajagopal J, Slavov N, Holmes D, Jurk D, Kirkland J, Lagnado A, Tchkonia T, Abraham K, Dibattista A, Fridell Y, Howcroft T, Jhappan C, Montes V, Prabhudas M, Resat H, Taylor V, Kumar M, Suryadevara V, Cigarroa F, Cohn R, Cortes T, Courtois E, Chuang J, Davé M, Domanskyi S, Enninga E, Eryilmaz G, Espinoza S, Gelfond J, Kirkland J, Kuchel G, Kuo C, Lehman J, Aguayo-Mazzucato C, Meves A, Rani M, Sanders S, Thibodeau A, Tullius S, Ucar D, White B, Wu Q, Xu M, Yamaguchi S, Assarzadegan N, Cho C, Hwang I, Hwang Y, Xi J, Adeyi O, Aliferis C, Bartolomucci A, Dong X, DuFresne-To M, Ikramuddin S, Johnson S, Nelson A, Niedernhofer L, Revelo X, Trevilla-Garcia C, Sedivy J, Thompson E, Robbins P, Wang J, Aird K, Alder J, Beaulieu D, Bueno M, Calyeca J, Chamucero-Millaris J, Chan S, Chung D, Corbett A, Gorbunova V, Gowdy K, Gurkar A, Horowitz J, Hu Q, Kaur G, Khaliullin T, Lafyatis R, Lanna S, Li D, Ma A, Morris A, Muthumalage T, Peters V, Pryhuber G, Reader B, Rosas L, Sembrat J, Shaikh S, Shi H, Stacey S, Croix C, Wang C, Wang Q, Watts A, Gu L, Lin Y, Rabinovitch P, Sweetwyne M, Artyomov M, Ballentine S, Chheda M, Davies S, DiPersio J, Fields R, Fitzpatrick J, Fulton R, Imai S, Jain S, Ju T, Kushnir V, Link D, Ben Major M, Oh S, Rapp D, Rettig M, Stewart S, Veis D, Vij K, Wendl M, Wyczalkowski M, Craft J, Enninful A, Farzad N, Gershkovich P, Halene S, Kluger Y, VanOudenhove J, Xu M, Yang J, Yang M. NIH SenNet Consortium to map senescent cells throughout the human lifespan to understand physiological health. Nature Aging 2022, 2: 1090-1100. PMID: 36936385, PMCID: PMC10019484, DOI: 10.1038/s43587-022-00326-5.
- Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies.Leveille E, Kothari S, Müschen M. Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies. Blood Cancer Discovery 2022, 4: 8-11. PMID: 36534735, PMCID: PMC9816816, DOI: 10.1158/2643-3230.bcd-22-0180.
- Recruited monocytes/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosisÖz H, Cheng E, Di Pietro C, Tebaldi T, Biancon G, Zeiss C, Zhang P, Huang P, Esquibies S, Britto C, Schupp J, Murray T, Halene S, Krause D, Egan M, Bruscia E. Recruited monocytes/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosis. Cell Reports 2022, 41: 111797. PMID: 36516754, PMCID: PMC9833830, DOI: 10.1016/j.celrep.2022.111797.
- NIH SenNet Consortium to map senescent cells throughout the human lifespan to understand physiological healthLee P, Benz C, Blood P, Börner K, Campisi J, Chen F, Daldrup-Link H, De Jager P, Ding L, Duncan F, Eickelberg O, Fan R, Finkel T, Furman D, Garovic V, Gehlenborg N, Glass C, Heckenbach I, Joseph Z, Katiyar P, Kim S, Königshoff M, Kuchel G, Lee H, Lee J, Ma J, Ma Q, Melov S, Metis K, Mora A, Musi N, Neretti N, Passos J, Rahman I, Rivera-Mulia J, Robson P, Rojas M, Roy A, Scheibye-Knudsen M, Schilling B, Shi P, Silverstein J, Suryadevara V, Xie J, Wang J, Wong A, Niedernhofer L, Wang S, Anvari H, Balough J, Benz C, Bons J, Brenerman B, Evans W, Gerencser A, Gregory H, Hansen M, Justice J, Kapahi P, Murad N, O’Broin A, Pavone M, Powell M, Scott G, Shanes E, Shankaran M, Verdin E, Winer D, Wu F, Adams A, Blood P, Bueckle A, Cao-Berg I, Chen H, Davis M, Filus S, Hao Y, Hartman A, Hasanaj E, Helfer J, Herr B, Joseph Z, Molla G, Mou G, Puerto J, Quardokus E, Ropelewski A, Ruffalo M, Satija R, Schwenk M, Scibek R, Shirey W, Sibilla M, Welling J, Yuan Z, Bonneau R, Christiano A, Izar B, Menon V, Owens D, Phatnani H, Smith C, Suh Y, Teich A, Bekker V, Chan C, Coutavas E, Hartwig M, Ji Z, Nixon A, Dou Z, Rajagopal J, Slavov N, Holmes D, Jurk D, Kirkland J, Lagnado A, Tchkonia T, Abraham K, Dibattista A, Fridell Y, Howcroft T, Jhappan C, Montes V, Prabhudas M, Resat H, Taylor V, Kumar M, Suryadevara V, Cigarroa F, Cohn R, Cortes T, Courtois E, Chuang J, Davé M, Domanskyi S, Enninga E, Eryilmaz G, Espinoza S, Gelfond J, Kirkland J, Kuchel G, Kuo C, Lehman J, Aguayo-Mazzucato C, Meves A, Rani M, Sanders S, Thibodeau A, Tullius S, Ucar D, White B, Wu Q, Xu M, Yamaguchi S, Assarzadegan N, Cho C, Hwang I, Hwang Y, Xi J, Adeyi O, Aliferis C, Bartolomucci A, Dong X, DuFresne-To M, Ikramuddin S, Johnson S, Nelson A, Niedernhofer L, Revelo X, Trevilla-Garcia C, Sedivy J, Thompson E, Robbins P, Wang J, Aird K, Alder J, Beaulieu D, Bueno M, Calyeca J, Chamucero-Millaris J, Chan S, Chung D, Corbett A, Gorbunova V, Gowdy K, Gurkar A, Horowitz J, Hu Q, Kaur G, Khaliullin T, Lafyatis R, Lanna S, Li D, Ma A, Morris A, Muthumalage T, Peters V, Pryhuber G, Reader B, Rosas L, Sembrat J, Shaikh S, Shi H, Stacey S, Croix C, Wang C, Wang Q, Watts A, Gu L, Lin Y, Rabinovitch P, Sweetwyne M, Artyomov M, Ballentine S, Chheda M, Davies S, DiPersio J, Fields R, Fitzpatrick J, Fulton R, Imai S, Jain S, Ju T, Kushnir V, Link D, Ben Major M, Oh S, Rapp D, Rettig M, Stewart S, Veis D, Vij K, Wendl M, Wyczalkowski M, Craft J, Enninful A, Farzad N, Gershkovich P, Halene S, Kluger Y, VanOudenhove J, Xu M, Yang J, Yang M. NIH SenNet Consortium to map senescent cells throughout the human lifespan to understand physiological health. Nature Aging 2022, 2: 1090-1100. DOI: 10.1038/s43587-022-00326-5.
- Deconvolution of in vivo protein-RNA contacts using fractionated eCLIP-seqBiancon G, Busarello E, Joshi P, Lesch B, Halene S, Tebaldi T. Deconvolution of in vivo protein-RNA contacts using fractionated eCLIP-seq. STAR Protocols 2022, 3: 101823. PMCID: PMC9676202, DOI: 10.1016/j.xpro.2022.101823.
- Deconvolution of in vivo protein-RNA contacts using fractionated eCLIP-seqBiancon G, Busarello E, Joshi P, Lesch B, Halene S, Tebaldi T. Deconvolution of in vivo protein-RNA contacts using fractionated eCLIP-seq. STAR Protocols 2022, 3: 101823. PMID: 36595959, PMCID: PMC9676202, DOI: 10.1016/j.xpro.2022.101823.
- Plasma Proteomic Profiling Illustrates Endothelial and Complement Signature in Patients with Alcohol-Associated CirrhosisAllen C, Butt A, Zhao X, Li F, Bahel P, Chang C, Chun H, Gu S, Hwa J, Jakab S, Chen B, Garcia-Tsao G, Rinder H, To U, McConnell M, Lee A, Pine A. Plasma Proteomic Profiling Illustrates Endothelial and Complement Signature in Patients with Alcohol-Associated Cirrhosis. Blood 2022, 140: 8382-8383. DOI: 10.1182/blood-2022-162633.
- Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based AnalysisDi M, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis. Blood 2022, 140: 10818-10819. DOI: 10.1182/blood-2022-164915.
- Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based AnalysisDi M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Stempel J, Ma X, Huntington S. Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis. Blood 2022, 140: 10904-10906. DOI: 10.1182/blood-2022-164959.
- Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with RuxolitinibStempel J, Wang R, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Ma X, Podoltsev N. Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib. Blood 2022, 140: 11004-11006. DOI: 10.1182/blood-2022-165156.
- Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple MyelomaBrowning S, Liu Y, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Syam R, Gorshein E, DiAdamo A, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Wei W, Haims A, Neparidze N. Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma. Blood 2022, 140: 7308-7310. DOI: 10.1182/blood-2022-166325.
- Complex Formation between FANCD2 and the Splicing Factor SRSF1 Helps Prevent R-Loop Accumulation through mRNA Export RegulationHerrero A, Liang F, Dutta A, Huang Y, Liang Z, Gupta A, Lan L, Pillai M, Sung P, Kupfer G. Complex Formation between FANCD2 and the Splicing Factor SRSF1 Helps Prevent R-Loop Accumulation through mRNA Export Regulation. Blood 2022, 140: 5828-5829. DOI: 10.1182/blood-2022-166798.
- Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction TherapyLiu Y, Browning S, VanOudenhove J, Biancon G, Bar N, Parker T, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Haims A, Wei W, Neparidze N. Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy. Blood 2022, 140: 7086-7087. DOI: 10.1182/blood-2022-168109.
- U2AF1 Splicing Factor Mutations Affect RNA Subcellular Compartmentalization in Myeloid MalignanciesBiancon G, Busarello E, Lessard M, Courvan E, Escayola D, VanOudenhove J, Lee V, Krick M, Bewersdorf J, Neugebauer K, Tebaldi T, Halene S. U2AF1 Splicing Factor Mutations Affect RNA Subcellular Compartmentalization in Myeloid Malignancies. Blood 2022, 140: 1271-1272. DOI: 10.1182/blood-2022-170043.
- Improving Diversity, Equity, and Inclusion Education in Hematology/Oncology TrainingKress A, Lu B, Butt A, Christian J, Podoltsev N, Hurwitz M, Goldberg S, Burtness B, Isufi I, Latimore D, Lee A, Kunz P. Improving Diversity, Equity, and Inclusion Education in Hematology/Oncology Training. Blood 2022, 140: 5029-5030. DOI: 10.1182/blood-2022-170950.
- Gene Therapy Equity in Sickle Cell Disease: Distributional Cost-Effectiveness Analysis (DCEA) of Gene Therapy Vs. Standard-of-Care in Patients with Sickle Cell Disease in the United StatesGoshua G, Calhoun C, Cheng V, James L, Luviano A, Krishnamurti L, Pandya A. Gene Therapy Equity in Sickle Cell Disease: Distributional Cost-Effectiveness Analysis (DCEA) of Gene Therapy Vs. Standard-of-Care in Patients with Sickle Cell Disease in the United States. Blood 2022, 140: 1395-1396. DOI: 10.1182/blood-2022-157460.
- BCL6-Mediated Escape from Negative Selection Enables RAS-Driven B-Cell TransformationChan L, Hurtz C, Robinson M, Leveille E, Geng H, Caeser R, Xu L, Kume K, Xiao G, Müschen M. BCL6-Mediated Escape from Negative Selection Enables RAS-Driven B-Cell Transformation. Blood 2022, 140: 9177-9178. DOI: 10.1182/blood-2022-169946.
- A Phosphatase Membrane-Shuttle Enables Feedback Control of B-Cell SignalingLee J, Kume K, Robinson M, Sun R, Ma N, Chen Z, Xiao G, Cosgun K, Chan L, Leveille E, Klemm L, Vykunta V, Shy B, Geng H, Luger S, Litzow M, Marson A, Paietta E, Vaidehi N, Meffre E, Müschen M. A Phosphatase Membrane-Shuttle Enables Feedback Control of B-Cell Signaling. Blood 2022, 140: 1698-1699. DOI: 10.1182/blood-2022-170324.
- Divergent MYC- and BCL6-Driven Metabolic Programs Enable Dynamic Regulation of Cell Biomass in B-Cell MalignanciesKume K, Chen Z, Chan L, Robinson M, Leveille E, Lee J, Cosgun K, Arce D, Khanduja D, Klemm L, Müschen M. Divergent MYC- and BCL6-Driven Metabolic Programs Enable Dynamic Regulation of Cell Biomass in B-Cell Malignancies. Blood 2022, 140: 5900-5901. DOI: 10.1182/blood-2022-170396.
- A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell DiseaseGoshua G, Hauser R, Tormey C, Pandya A, Hendrickson J. A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease. Blood 2022, 140: 2147-2148. DOI: 10.1182/blood-2022-169099.
- Cost-Effectiveness of Caplacizumab without First-Line Therapeutic Plasma Exchange Vs. Standard-of-Care for Patients with Immune Thrombotic Thrombocytopenic Purpura: Setting Future Clinical Trial ThresholdsButt A, Lee A, Goshua G. Cost-Effectiveness of Caplacizumab without First-Line Therapeutic Plasma Exchange Vs. Standard-of-Care for Patients with Immune Thrombotic Thrombocytopenic Purpura: Setting Future Clinical Trial Thresholds. Blood 2022, 140: 1621-1622. DOI: 10.1182/blood-2022-170003.
- Structural Elements of the BCR Determine Permissiveness to Oncogenic RAS-Driven B-Cell TransformationChan L, Robinson M, Cosgun K, Yu X, Leveille E, Geng H, Müschen M. Structural Elements of the BCR Determine Permissiveness to Oncogenic RAS-Driven B-Cell Transformation. Blood 2022, 140: 8758-8759. DOI: 10.1182/blood-2022-170079.
- Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasmsPatnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia 2022, 36: 2934-2938. PMID: 36335264, DOI: 10.1038/s41375-022-01754-3.
- Human neutrophil development and functionality are enabled in a humanized mouse modelZheng Y, Sefik E, Astle J, Karatepe K, Öz HH, Solis AG, Jackson R, Luo HR, Bruscia EM, Halene S, Shan L, Flavell RA. Human neutrophil development and functionality are enabled in a humanized mouse model. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2121077119. PMID: 36269862, PMCID: PMC9618085, DOI: 10.1073/pnas.2121077119.
- Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic SyndromesZeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 2022, 36: 2939-2946. PMID: 36266326, DOI: 10.1038/s41375-022-01724-9.
- COVID-19 and antiphospholipid antibodiesButt A, Erkan D, Lee A. COVID-19 and antiphospholipid antibodies. Best Practice & Research Clinical Haematology 2022, 101402. PMCID: PMC9568270, DOI: 10.1016/j.beha.2022.101402.
- Treatment of myelodysplasia‐associated reactive, non‐interstitial granulomatous dermatitis with hydroxychloroquineChoi R, Bhullar S, Glusac E, Podoltsev N, Leventhal J. Treatment of myelodysplasia‐associated reactive, non‐interstitial granulomatous dermatitis with hydroxychloroquine. International Journal Of Dermatology 2022, 62: e398-e399. PMID: 36214463, DOI: 10.1111/ijd.16441.
- AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML).Stahl M, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Bewersdorf JP. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma & Leukemia 2022, 22 Suppl 2: S209-S210. PMID: 36163756, DOI: 10.1016/S2152-2650(22)01214-9.
- Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasmGupta A, Department of Medicine Y, Afinogenova Y, Podoltsev N, Danve A, Section of Rheumatology A, Section of Hematology D. Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm. European Journal Of Rheumatology 2022, 9: 215-216. PMID: 35156633, DOI: 10.5152/eurjrheum.2022.21097.
- Widespread association of the Argonaute protein AGO2 with meiotic chromatin suggests a distinct nuclear function in mammalian male reproductionGriffin KN, Walters BW, Li H, Wang H, Biancon G, Tebaldi T, Kaya CB, Kanyo J, Lam TT, Cox AL, Halene S, Chung JJ, Lesch BJ. Widespread association of the Argonaute protein AGO2 with meiotic chromatin suggests a distinct nuclear function in mammalian male reproduction. Genome Research 2022, 32: 1655-1668. PMID: 36109149, PMCID: PMC9528986, DOI: 10.1101/gr.276578.122.
- Bias Against International Medical Graduates in the Hematology/Oncology Fellowship Recruitment Process: Findings From a Nationwide Survey of Fellowship Program DirectorsButt A, Mankbadi M, Erikson C, Marshall A, Masselink LE, Tong G, Hafler J, Podoltsev N, Lee AI. Bias Against International Medical Graduates in the Hematology/Oncology Fellowship Recruitment Process: Findings From a Nationwide Survey of Fellowship Program Directors. JCO Oncology Practice 2022, 18: 783-787. PMID: 36108253, DOI: 10.1200/op.22.00219.
- COVID-19 and antiphospholipid antibodiesButt A, Erkan D, Lee A. COVID-19 and antiphospholipid antibodies. Best Practice & Research Clinical Haematology 2022, 35: 101402. PMID: 36494152, PMCID: PMC9568270, DOI: 10.1016/j.beha.2022.101402.
- Spatial profiling of chromatin accessibility in mouse and human tissuesDeng Y, Bartosovic M, Ma S, Zhang D, Kukanja P, Xiao Y, Su G, Liu Y, Qin X, Rosoklija GB, Dwork AJ, Mann JJ, Xu ML, Halene S, Craft JE, Leong KW, Boldrini M, Castelo-Branco G, Fan R. Spatial profiling of chromatin accessibility in mouse and human tissues. Nature 2022, 609: 375-383. PMID: 35978191, PMCID: PMC9452302, DOI: 10.1038/s41586-022-05094-1.
- Association of iron infusion reactions with ABO blood typeButt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type. European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.
- Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTCOlsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022, 140: 419-437. PMID: 34758074, PMCID: PMC9353153, DOI: 10.1182/blood.2021012057.
- 831 Proteasome inhibitor functional profiling in CTCLXu S, Lewis J, King A, Umlauf S, Carlson K, Foss F, Girardi M. 831 Proteasome inhibitor functional profiling in CTCL. Journal Of Investigative Dermatology 2022, 142: s144. DOI: 10.1016/j.jid.2022.05.845.
- Esophageal Graft-vs-Host Disease Presenting as Esophagitis Dissecans SuperficialisOgurick A, Liu C, Gowda L, Li D. Esophageal Graft-vs-Host Disease Presenting as Esophagitis Dissecans Superficialis. ACG Case Reports Journal 2022, 9: e00833. DOI: 10.14309/crj.0000000000000833.
- When competition is not enough: leveraging US policies to curb oral anticancer drug costsPotnis KC, Huntington SF. When competition is not enough: leveraging US policies to curb oral anticancer drug costs. The Lancet Oncology 2022, 23: 836-837. PMID: 35772451, DOI: 10.1016/s1470-2045(22)00297-2.
- Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic periodNeparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. Leukemia 2022, 36: 2136-2139. PMID: 35761025, PMCID: PMC9243711, DOI: 10.1038/s41375-022-01633-x.
- Abstract 5882: Birth characteristics and risk of early-onset myeloproliferative neoplasms in a population-based case-control studyPodoltsev N, Wang R, Wiemels J, Morimoto L, Metayer C, Ma X. Abstract 5882: Birth characteristics and risk of early-onset myeloproliferative neoplasms in a population-based case-control study. Cancer Research 2022, 82: 5882-5882. DOI: 10.1158/1538-7445.am2022-5882.
- Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysisDi M, Cui C, Kothari S, Zeidan AM, Podoltsev NA, Neparidze N, Shallis R, Wang R, Ma X, Huntington SF. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Advances 2022, 6: 3339-3342. PMID: 35240689, PMCID: PMC9198937, DOI: 10.1182/bloodadvances.2021006934.
- Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses.Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses. Journal Of Clinical Oncology 2022, 40: 7554-7554. DOI: 10.1200/jco.2022.40.16_suppl.7554.
- Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristicsGisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.
- Sex differences in long-term outcomes of patients with deep vein thrombosisChan SM, Brahmandam A, Valcarce-Aspegren M, Zhuo H, Zhang Y, Tonnessen BH, Lee AI, Chaar C. Sex differences in long-term outcomes of patients with deep vein thrombosis. Vascular 2022, 31: 994-1002. PMID: 35502988, DOI: 10.1177/17085381221097746.
- Inflammasome activation in infected macrophages drives COVID-19 pathologySefik E, Qu R, Junqueira C, Kaffe E, Mirza H, Zhao J, Brewer JR, Han A, Steach HR, Israelow B, Blackburn HN, Velazquez SE, Chen YG, Halene S, Iwasaki A, Meffre E, Nussenzweig M, Lieberman J, Wilen CB, Kluger Y, Flavell RA. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 2022, 606: 585-593. PMID: 35483404, PMCID: PMC9288243, DOI: 10.1038/s41586-022-04802-1.
- Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort StudiesFigueiredo JC, Hirsch FR, Kushi LH, Nembhard WN, Crawford JM, Mantis N, Finster L, Merin NM, Merchant A, Reckamp KL, Melmed GY, Braun J, McGovern D, Parekh S, Corley DA, Zohoori N, Amick BC, Du R, Gregersen PK, Diamond B, Taioli E, Sariol C, Espino A, Weiskopf D, Gifoni A, Brien J, Hanege W, Lipsitch M, Zidar DA, McAlearney A, Wajnberg A, LaBaer J, Lewis E, Binder RA, Moormann AM, Forconi C, Forrester S, Batista J, Schieffelin J, Kim D, Biancon G, VanOudenhove J, Halene S, Fan R, Barouch DH, Alter G, Pinninti S, Boppana SB, Pati SK, Latting M, Karaba AH, Roback J, Sekaly R, Neish A, Brincks AM, Granger DA, Karger AB, Thyagarajan B, Thomas SN, Klein SL, Cox AL, Lucas T, Furr-Holden D, Key K, Jones N, Wrammerr J, Suthar M, Wong S, Bowman NM, Simon V, Richardson LD, McBride R, Krammer F, Rana M, Kennedy J, Boehme K, Forrest C, Granger SW, Heaney CD, Lapinski M, Wallet S, Baric RS, Schifanella L, Lopez M, Fernández S, Kenah E, Panchal AR, Britt WJ, Sanz I, Dhodapkar M, Ahmed R, Bartelt LA, Markmann AJ, Lin JT, Hagan RS, Wolfgang MC, Skarbinski J. Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infectious Diseases 2022, 9: ofac171. PMID: 35765315, PMCID: PMC9129196, DOI: 10.1093/ofid/ofac171.
- Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell LymphomaAvery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.
- Integrative genome-wide analysis reveals EIF3A as a key downstream regulator of translational repressor protein Musashi 2 (MSI2)Karmakar S, Ramirez O, Paul KV, Gupta AK, Kumari V, Botti V, de los Mozos IR, Neuenkirchen N, Ross RJ, Karanicolas J, Neugebauer KM, Pillai MM. Integrative genome-wide analysis reveals EIF3A as a key downstream regulator of translational repressor protein Musashi 2 (MSI2). NAR Cancer 2022, 4: zcac015. PMID: 35528200, PMCID: PMC9070473, DOI: 10.1093/narcan/zcac015.
- SYK and ZAP70 kinases in autoimmunity and lymphoid malignanciesLeveille E, Chan LN, Mirza AS, Kume K, Müschen M. SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies. Cellular Signalling 2022, 94: 110331. PMID: 35398488, DOI: 10.1016/j.cellsig.2022.110331.
- In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia 2022, 36: 1313-1323. PMID: 35273342, PMCID: PMC9103411, DOI: 10.1038/s41375-022-01536-x.
- Association of renalase with clinical outcomes in hospitalized patients with COVID-19Safdar B, Wang M, Guo X, Cha C, Chun HJ, Deng Y, Dziura J, El-Khoury JM, Gorelick F, Ko AI, Lee AI, Safirstein R, Simonov M, Zhou B, Desir GV. Association of renalase with clinical outcomes in hospitalized patients with COVID-19. PLOS ONE 2022, 17: e0264178. PMID: 35259186, PMCID: PMC8903289, DOI: 10.1371/journal.pone.0264178.
- A guide to molecular and functional investigations of platelets to bridge basic and clinical sciencesTyagi T, Jain K, Gu S, Qiu M, Gu V, Melchinger H, Rinder H, Martin K, Gardiner E, Lee A, Tang W, Hwa J. A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences. Nature Cardiovascular Research 2022, 1: 223-237. PMID: 37502132, PMCID: PMC10373053, DOI: 10.1038/s44161-022-00021-z.
- A guide to molecular and functional investigations of platelets to bridge basic and clinical sciencesTyagi T, Jain K, Gu S, Qiu M, Gu V, Melchinger H, Rinder H, Martin K, Gardiner E, Lee A, Tang W, Hwa J. A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences. Nature Cardiovascular Research 2022, 1: 223-237. PMID: 37502132, PMCID: PMC10373053, DOI: 10.1038/s44161-022-00021-z.
- Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignanciesBiancon G, Joshi P, Zimmer JT, Hunck T, Gao Y, Lessard MD, Courchaine E, Barentine AES, Machyna M, Botti V, Qin A, Gbyli R, Patel A, Song Y, Kiefer L, Viero G, Neuenkirchen N, Lin H, Bewersdorf J, Simon MD, Neugebauer KM, Tebaldi T, Halene S. Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies. Molecular Cell 2022, 82: 1107-1122.e7. PMID: 35303483, PMCID: PMC8988922, DOI: 10.1016/j.molcel.2022.02.025.
- MYOCARDIAL IMPACT OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) SECRETOMES IN CARDIO-ONCOLOGY PATIENTSKwan J, Vanoudenhove J, Halder S, Biancon G, Jain K, Chakraborty R, Lustberg M, Pusztai L, Campbell S, Zhao H, Halene S, Hwa J. MYOCARDIAL IMPACT OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) SECRETOMES IN CARDIO-ONCOLOGY PATIENTS. Journal Of The American College Of Cardiology 2022, 79: 1912. DOI: 10.1016/s0735-1097(22)02903-5.
- DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML TransformationJawad M, Afkhami M, Ding Y, Zhang X, Li P, Young K, Xu ML, Cui W, Zhao Y, Halene S, Al-Kali A, Viswanatha D, Chen D, He R, Zheng G. DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. Frontiers In Oncology 2022, 12: 849376. PMID: 35296003, PMCID: PMC8918526, DOI: 10.3389/fonc.2022.849376.
- Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopeniaGoshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia. American Journal Of Hematology 2022, 98: 122-130. PMID: 35147241, PMCID: PMC9365880, DOI: 10.1002/ajh.26497.
- The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysisGoksu SY, Ozer M, Goksu BB, Wang R, Khatib J, Patel PA, Vusirikala M, Cole S, Seyhanli A, Collins RH, Chung S, Zeidan AM, Madanat YF. The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. Leukemia & Lymphoma 2022, 63: 1651-1659. PMID: 35133215, DOI: 10.1080/10428194.2022.2032034.
- Adenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysisPischel L, Patel KM, Goshua G, Omer SB. Adenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysis. Clinical Infectious Diseases 2022, 75: 1179-1186. PMID: 35134164, PMCID: PMC9383370, DOI: 10.1093/cid/ciac080.
- Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United StatesBewersdorf JP, Prozora S, Podoltsev NA, Shallis R, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.
2021
- Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donorJacobs JW, Guarente J, Hendrickson JE, Tormey CA, Bar N. Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donor. Journal Of Clinical Apheresis 2021, 37: 316-319. PMID: 34953078, DOI: 10.1002/jca.21962.